Cargando…

Assessment of chemotherapy‐induced neurotoxicity using a point‐of‐care nerve conduction study device

BACKGROUND: Management for chemotherapy‐induced peripheral neuropathy (CIPN) includes prompt recognition and dose reduction or discontinuation of the neurotoxic agents. CIPN remains under‐detected in routine clinical practice and better methods for its early detection are warranted. AIMS: To evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jokimäki, Anna, Iivanainen, Sanna, Mikkonen, Raija, Mika, Kallio, Koivunen, Jussi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875618/ https://www.ncbi.nlm.nih.gov/pubmed/35818348 http://dx.doi.org/10.1002/cnr2.1677

Ejemplares similares

Quantitative assessment of chemotherapy‐induced peripheral neurotoxicity using a point‐of‐care nerve conduction device
por: Matsuoka, Ayumu, et al.
Publicado: (2016)

Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection
por: Iivanainen, Sanna, et al.
Publicado: (2020)

Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers
por: Tikkanen, Antti, et al.
Publicado: (2020)

Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study
por: Kuusisalo, Saara, et al.
Publicado: (2022)

Tetracyclines increase the survival of NSCLC patients treated with EGFR TKIs: a retrospective nationwide registry study
por: Alanen, Virve, et al.
Publicado: (2020)

Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies
por: Iivanainen, Sanna, et al.
Publicado: (2021)

ePRO symptom follow-up of colorectal cancer patients receiving oxaliplatin-based adjuvant chemotherapy is feasible and enhances the quality of patient care: a prospective multicenter study
por: Iivanainen, Sanna, et al.
Publicado: (2023)

Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors
por: Iivanainen, Sanna, et al.
Publicado: (2019)

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
por: Park, Susanna B., et al.
Publicado: (2012)

Follow-Up of Cancer Patients Receiving Anti-PD-(L)1 Therapy Using an Electronic Patient-Reported Outcomes Tool (KISS): Prospective Feasibility Cohort Study
por: Iivanainen, Sanna, et al.
Publicado: (2020)

ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study
por: Iivanainen, Sanna, et al.
Publicado: (2019)

Digital Monitoring and Management of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Treated With Cancer Immunotherapy and Its Impact on Quality of Clinical Care: Interview and Survey Study Among Health Care Professionals and Patients
por: Schmalz, Oliver, et al.
Publicado: (2020)

Validity and reliability of a point‐of‐care nerve conduction device in diabetes patients
por: Shibata, Yuka, et al.
Publicado: (2019)

Assessment of diabetic polyneuropathy in Zanzibar: Comparison between traditional methods and an automated point-of-care nerve conduction device
por: Vogt, Elinor C., et al.
Publicado: (2017)

Reliability and Validity of a Point-of-Care Sural Nerve Conduction Device for Identification of Diabetic Neuropathy
por: Lee, Justin A., et al.
Publicado: (2014)

Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability
por: Hill, Andrew, et al.
Publicado: (2010)

The prognostic and predictive roles of plasma C‐reactive protein and PD‐L1 in non‐small cell lung cancer
por: Kuusisalo, Saara, et al.
Publicado: (2023)

Previous radiotherapy improves treatment responses and causes a trend toward longer time to progression among patients with immune checkpoint inhibitor-related adverse events
por: Jokimäki, Anna, et al.
Publicado: (2023)

Correction: Reliability and Validity of a Point-of-Care Sural Nerve Conduction Device for Identification of Diabetic Neuropathy
Publicado: (2014)

Point‐of‐care nerve conduction device predicts the severity of diabetic polyneuropathy: A quantitative, but easy‐to‐use, prediction model
por: Kamiya, Hideki, et al.
Publicado: (2020)

Neurotoxicity of cancer chemotherapy
por: Yang, Miyoung, et al.
Publicado: (2013)

Point-of-care devices: the next frontier in personalized chemotherapy
por: Borba, Maria Amélia Carlos Souto Maior, et al.
Publicado: (2017)

Allantoin attenuates deficits of behavioural and motor nerve conduction in an animal model of cisplatin‐induced neurotoxicity in rats
por: N S, Vindya, et al.
Publicado: (2019)

Mechanisms of Chemotherapy-Induced Neurotoxicity
por: Was, Halina, et al.
Publicado: (2022)

Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity
por: Alberti, Paola, et al.
Publicado: (2021)

A Cross-Sectional Study of Sub-Basal Corneal Nerve Reduction Following Neurotoxic Chemotherapy
por: Chiang, Jeremy Chung Bo, et al.
Publicado: (2021)

Oxaliplatin-induced blood brain barrier loosening: a new point of view on chemotherapy-induced neurotoxicity
por: Branca, Jacopo Junio Valerio, et al.
Publicado: (2018)

Difference in normal limit values of nerve conduction parameters between Westerners and Japanese people might need to be considered when diagnosing diabetic polyneuropathy using a Point‐of‐Care Sural Nerve Conduction Device (NC‐stat®/DPNCheck™)
por: Hirayasu, Kazuhiro, et al.
Publicado: (2018)

Self-Reported Assessment of the Socio-Economic Impact of Anticancer Chemotherapy-Related Neurotoxicity
por: Cavaletti, Guido, et al.
Publicado: (2023)

Programming mobile devices: an introduction for practitioners
por: Mikkonen, Tommi
Publicado: (2007)

Validity of a point-of-care nerve conduction device for polyneuropathy identification in older adults with diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes
por: Scarr, Daniel, et al.
Publicado: (2018)

Comprehensive neurotoxicity assessment.
por: Kulig, B M
Publicado: (1996)

Association between Diabetic Peripheral Neuropathy as Measured Using a Point-of-Care Sural Nerve Conduction Device and Urinary Albumin Excretion in Patients with Type 2 Diabetes
por: Fukuda, Tatsuya, et al.
Publicado: (2023)

Cannabinoids: an Effective Treatment for Chemotherapy-Induced Peripheral Neurotoxicity?
por: Cavaletti, Guido, et al.
Publicado: (2021)

A review of movement disorders in chemotherapy-induced neurotoxicity
por: Wang, Allison B., et al.
Publicado: (2021)

Dose Effects of Oxaliplatin on Persistent and Transient Na(+) Conductances and the Development of Neurotoxicity
por: Park, Susanna B., et al.
Publicado: (2011)

Combining targeted drugs to overcome and prevent resistance of solid cancers with some stem-like cell features
por: Jokinen, Elina, et al.
Publicado: (2014)

Independent and concomitant associations of gestational diabetes and maternal obesity to perinatal outcome: A register-based study
por: Ijäs, Hilkka, et al.
Publicado: (2019)

In vitro techniques for the assessment of neurotoxicity.
por: Harry, G J, et al.
Publicado: (1998)

An ecotoxicological view on neurotoxicity assessment
por: Legradi, J. B., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6gv9d8dc82ml10h7g9go0sol38